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Abstract
Background Recent evidence questions the role of intra-aortic
balloon counterpulsation (IABP) in the treatment of acute
myocardial infarction (AMI) complicated by cardiogenic
shock (CS). An area of increasing interest is the use of IABP
for persistent ischaemia (PI). We analysed the use of IABP in
patients with AMI complicated by CS or PI.
Methods From 2008 to 2010, a total of 4076 patients were
admitted to our hospital for primary percutaneous coronary
intervention (PCI) for AMI. Out of those, 239 patients
received an IABP either because of CS or because of PI.
Characteristics and outcome of those patients are
investigated.
Results The mean age of the study population was 64±
11 years; 75 % were male patients. Of the patients, 63 %
had CS and 37 % had PI. Patients with CS had a 30-day
mortality rate of 36 %; 1-year mortality was 41 %. Patients
with PI had a 30-day mortality rate of 7 %; 1-year mortality
was 11 %.
Conclusions Mortality in patients admitted for primary PCI
because of AMI complicated by CS is high despite IABP use.
Outcome in patients treated with IABP for PI is favourable
and mandates further prospective studies.
Keywords Intra-aortic balloon counterpulsation .
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Introduction
Acute myocardial infarction (AMI) is complicated by
cardiogenic shock (CS) in approximately 5–10 % of patients
[1, 2]. Intra-aortic balloon counterpulsation (IABP) has been
used as a haemodynamic support system for patients with
AMI complicated by CS since 1968 [3]. Treatment with
IABP is supposed to increase cardiac output by more effective
emptying of the left ventricle, decreasing workload and
thereby oxygen demand of the heart, and to reducemyocardial
ischaemia by augmentation of coronary perfusion [4, 5].
Evidence for IABP use in patients with AMI complicated
by CS is largely based upon pathophysiological
considerations and non-randomised, small trials of patients
treated with thrombolytic therapy [6]. However, the most
recent large randomised trial on the use of IABP in patients
with AMI complicated by CS showed no benefit on 30-day
mortality [7]. As a result, the efficacy of IABP to treat patients
with CS has been questioned.
In contrast, an area of increasing interest is the use of IABP
in patients with persistent ischaemia (PI) after primary PCI for
AMI (no-reflow phenomenon). Because PI is thought to be
reversible over time (within hours to days), decreasing the
workload of the myocardium and increasing coronary blood
flow by IABP is suggested to limit the final size of the
infarcted territory [8].
In this paper, we report our complete experience with the
use of IABP in acute myocardial infarction, either as treatment
for cardiogenic shock or to treat persistent ischaemia, over a
period of 3 years.
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All patients admitted to the Catharina Hospital Eindhoven for
primary PCI in AMI (with ST elevation) during a 3-year
period (1 January 2008 to 31 December 2010) were studied
(Fig. 1). Of all patients, we analysed those who survived the
interventional procedure and were treated by IABP. Baseline
characteristics including cardiovascular risk factors, patient
history, electrocardiograms, coronary anatomy, indication for
IABP insertion, haemodynamic parameters at time of IABP
insertion and possible complications were acquired from
patient medical records and local databases.
Patients were retrospectively divided into two subgroups,
based on the indication for treatment with IABP, i.e. CS or PI
(without CS). CS was defined as a persistent state of
hypotension (systolic blood pressure <90 mmHg or mean
arterial pressure 30 mmHg lower than baseline) and clinical
signs of CS (abnormal mental status, cold clammy skin,
oliguria). Patients in whom IABP was inserted because of
mechanical complications of AMI (ventricular septal rupture,
papillary muscle rupture) were assigned to the CS group by
definition.
PI was defined as persistent or recurrent chest pain and ST
elevation despite successful epicardial reperfusion therapy
(no-reflow phenomenon), failed primary PCI with persistent
chest pain and STelevation, or bridge to CABG. Recurrent ST
elevation was defined as return of ST elevation before leaving
the catheterisation laboratory after initial regression due to
successful reperfusion therapy.
Patients presenting with both CS and PI were assigned to
the CS group by definition.
The Datascope 300 CS console, combinedwith theMaquet
Sensation 7 Fr. 40 cc balloon, was used in all patients (Maquet
Inc, Wayne, NJ).
IABP-related complications were defined as peripheral
ischaemia requiring IABP removal (absence of peripheral
pulsation combined with white colouration of the leg on the
side of IABP insertion), bleeding requiring transfusion or need
for vascular surgery, and infection because of IABP insertion
(fever and signs of inflammation, combined with increased C-
reactive protein levels (>6 mg/l)).
Follow-up and data collection
Follow-up was obtained at the time of IABP removal, hospital
discharge, 30-day and 1-year follow-up. Outcome measures
were all-cause mortality within 30 days and all-cause
mortality at 1 year. Vital status was obtained by contacting
the patient’s treating cardiologist or general physician.
Statistical analysis
Discrete variables are presented as percentages, while
continuous variables are presented as mean ± standard
deviations. Discrete variables were compared using the X2
or Fisher’s exact test as appropriate. Continuous variables
were compared using the Student’s t test or Mann–Whitney-
U test as appropriate.
Since hazard ratios of the covariates are not constant over
time, we used multivariate regression analysis to identify
predictors of 30-day and 1-year mortality.
The patients lost to follow-up were censored at the date of
last contact (in all cases the date of hospital discharge).
A limited number of variables were preselected for
multivariate regression analysis according to the size of the
study population. The preselected variables were age, CS,
cardiopulmonary resuscitation, use of antiarrhythmic drugs,
use of inotropic agents and coronary artery bypass grafting
(CABG).
The acquired data were analysed using IBM Statistical
Package for Social Sciences (SPSS) for Windows Version
19.0.0.1 (IBM Corporation, Armonk, NY). All statistical tests
were two-tailed and p -value <0.05 was considered statistically
significant.
Results
Baseline characteristics and in-hospital outcome
In total, 4076 patients were admitted to the hospital for AMI.
Of those patients, 42 (1 %) were moribund and died in the
catheterisation laboratory and were excluded from this
analysis. Overall in-hospital mortality was 2.6 %. In 239
Fig. 1 Flowchart. Patients admitted for acute myocardial infarction to the
Catharina Hospital Eindhoven, period 2008–2010
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patients (5.9 %), an IABP was inserted at the catheterisation
laboratory during or immediately following the revas-
cularisation procedure (Fig. 1).
Reperfusion was achieved in 87 % of the patients
receiving IABP (study population), either by primary PCI
(49 %) or by emergency CABG if primary PCI failed or
was considered inferior to emergency CABG (38 %).
Table 1 shows the baseline characteristics of these patients
and the subgroups based upon indication for IABP
insertion (CS or PI).
Table 1 Baseline characteristics of patients receiving intra-aortic balloon counterpulsation
Total (n =239) Indication for IABP insertion p-value
Cardiogenic shock (n=151) Persistent ischaemia (n=88)
Age (years) 64±11 64±11 65±11 0.87
Male sex (% (n)) 75 (180) 74 (111) 78 (69) 0.40
Risk factors
Hypertension (% (n)) 40 (96) 38 (59) 42 (37) 0.65
Diabetes mellitus (% (n)) 20 (47) 20 (30) 19 (17) 0.92
Hypercholesterolaemia (% (n)) 24 (58) 20 (30) 32 (28) 0.04
Smoking (% (n)) 32 (77) 31 (47) 34 (30) 0.58
Renal insufficiency (% (n)) 5 (12) 4 (6) 7 (6) 0.37
Peripheral arterial disease (% (n)) 8 (20) 7 (10) 11 (10) 0.20
History of
Coronary disease (% (n)) 32 (77) 29 (43) 39 (34) 0.11
CVA/TIA (% (n)) 9 (22) 9 (14) 9 (8) 0.96
Atrial fibrillation (% (n)) 3 (8) 4 (6) 2 (2) 0.71
Systolic blood pressure (mmHg) 96±30 80±27 121±20 <0.01
Diastolic blood pressure (mmHg) 55±18 47±18 68±14 <0.01
Heart rate (beats per minute) 92±22 95±25 84±18 <0.01
Out of hospital cardiac arrest (% (n)) 25 (60) 32 (48) 14 (12) <0.01
Mechanical ventilation (% (n)) 23 (55) 29 (44) 13 (11) <0.01
Location of STEMI
Anterior/septal (% (n)) 43 (103) 40 (61) 48 (42) 0.27
Inferior/posterior (% (n)) 34 (81) 37 (56) 28 (25) 0.17
Undetermined/pan-ischaemia (% (n)) 22 (53) 22 (33) 22 (20) 0.88
Three vessel/left main stem coronary disease (% (n)) 62 (147) 61 (92) 63 (55) 0.86
Mechanical complication (% (n)) 8 (20) 13 (20) 0 (0) <0.01
Reperfusion therapy
Primary PCI (% (n)) 49 (118) 59 (89) 33 (29) <0.01
CABG (% (n)) 38 (91) 33 (50) 47 (41) 0.04
No reperfusion or thrombolytic therapy (% (n)) 13 (30) 8 (12) 21 (18) <0.01
Indication for IABP-implantation
Reduction of ischaemia (% (n)) 37 (88) 0 (0) 100 (88)
Cardiogenic shock (% (n)) 63 (151) 100 (151) 0 (0)
Complications during hospitalisation
Use of inotropic agents (% (n)) 78 (186) 93 (140) 52 (46) <0.01
Use of antiarrhythmic agents (% (n)) 38 (90) 45 (68) 25 (22) <0.01
Renal failure (renal replacement therapy) (% (n)) 3 (6) 3 (5) 1 (1) 0.42
IABP running time
≤1 day (% (n)) 38 (91) 31 (46) 51 (45) <0.01
≥1 days (% (n)) 62 (148) 70 (105) 49 (43) <0.01
Data are presented as mean ± SD or percentages
CABG indicates coronary artery bypass grafting;CVA cerebrovascular event, IABP intra-aortic balloon pump, PCI percutaneous coronary intervention,
STEMI ST-segment elevation myocardial infarction TIA transient ischemic attack
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Overall, patients had multiple risk factors for coronary
artery disease. At the time of presentation, 25% of the patients
were resuscitated and 23 % were mechanically ventilated. In
63 % of the patients, the indication for IABP placement was
CS, in 37 % PI. The baseline systolic and diastolic blood
pressures were significantly higher in the patients treated for
PI, while the need for inotropic agents (dobutamine and
norepinephrine) was significantly lower. The IABP was used
during ≤1 day in 38 % of the patients, 62 % of the patients
were supported by IABP ≥1 days.
There was a relatively low incidence of IABP-related
complications of 4 %, due to major bleeding (2 %) and
ischaemia (2 %). Balloon rupture occurred in 1 patient.
Thirty-day and one-year follow-up
Follow-up at 30-days and 1-year was obtained in 98 % of the
patients. Four patients (2 %) were lost during follow-up due to
transportation to their native country.
Cumulative 30-day mortality and 1-year mortality for
patients treated with IABP was 26 % and 31 %, respectively.
Figure 2 shows the Kaplan-Meier survival curves of the two
groups classified by indication of IABP use. The patients with
CS had a 30-day mortality of 36 % and a 1-year mortality of
41 %. The patients treated with IABP because of PI had a 30-
day mortality of 7 %; 1-year mortality was 11 %.
The results from the multivariate regression analyses are
shown in Table 2. The presence of CS (OR, 4.7; 95% CI, 1.8–
12.4) was independently associated with higher 30-day
mortality.
For long-term survival, we performed a subanalysis of all
patients successfully weaned from IABP after haemodynamic
stabilisation (Table 2). Older age (OR, 1.04; 95 % CI, 1.0–
1.08) was independently associated with higher 1-year
mortality.
In both 30-daymortality (OR, 0.3; 95%CI, 0.1–0.6) and 1-
year mortality (OR, 0.3; 95 % CI, 0.1–0.8), CABG was an
independent predictor for better survival.
Discussion
This study describes IABP use in a population of consecutive
patients over a 3-year period presenting with AMI, in whom
either cardiogenic shock or persistent ischaemia was present
after (successful or failed) primary PCI. It does not compare
two groups of patients, but solely reflects on two different
indications of IABP use. On the one hand, it confirms the poor
outcome of CS, but at the same time, it opens the window for a
potentially better treatment of another group of patients with a
poor prognosis, i.e. patients with persistent ischaemia.
In patients with CS, 30-day survival was 64 %, in
accordance with the existing literature [7, 9].
In contrast, in patients with PI 30-day survival and 1-year
survival were high (93 % and 89 %, respectively). Although
there are no randomised data in the literature to compare
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Fig. 2 One-year survival of patients treated with intra-aortic balloon counterpulsation. Panel A shows the KaplanMeier curve of the patients treated with
IABP for CS. Panel B shows the Kaplan Meier curve of the patients treated with IABP for PI
survival of patients treated with IABP for PI, survival of
patients with PI treated medically is much worse [10, 11].
Reperfusion by CABG was independently associated with
better 30-day survival, most likely because of selection bias
through acceptance for emergency CABG.
In this study, there were few complications of IABP use
(4 %), comparable with the percentage of complications in the
IABP-SHOCK II trial.
IABP as treatment of cardiogenic shock
Patients treated with IABP in our study who met the criteria of
CS had a 30-day survival of 64 %, which is in line with the
recent IABP-SHOCK II trial, showing a 30-day survival of
61 %. These survival rates are high when compared with
other, older studies [12, 13], most likely because of the high
percentage of early revascularisation (90 %) [14, 15]. The
IABP-SHOCK II trial was the first randomised controlled trial
on the use of IABP in patients presenting with AMI
complicated by CS where reperfusion was achieved mostly
by PCI and showed no reduction in short-term mortality [7].
This landmark study has some limitations which were
discussed recently [16]. The study was underpowered due to
the 30-day mortality which was significantly lower than
expected. Also, there was a relatively high rate of crossover
in the control group (10 %) and there was a trend towards an
increase in the use of left ventricular assist devices in the
control group. These limitations are inherent in such a study
in ‘back-against-the-wall’ patients, but could mask the
potential benefit of IABP use.
Nonetheless, these results question if IABP deserves
its place as routine treatment of patients with AMI
complicated by CS, but do not exclude a beneficial effect
in some patients. The challenge is to find a way to
distinguish between those patients and not abandon such
a potentially life-saving treatment regardlessly. At least,
it can be expected that a beneficial effect of augmented
diastolic pressure only plays a role in case of PI with
exhausted autoregulation. In case of CS without PI,
improved coronary blood flow is unlikely.
IABP as treatment of persistent ischaemia
Use of IABP after successful epicardial reperfusion com-
plicated by PI (no-reflow phenomenon), or after failed PCI,
is an area which has not been investigated extensively. This
no-reflow phenomenon is attributable to a variety of factors,
including micro-embolisation, spasm, intramyocardial
oedema and other entities incompletely understood [17], but
leading to enlargement of the area of myocardial necrosis.
In a number of these patients, dramatic relief of ischaemia
occurs after insertion of IABP, most likely due to afterload
reduction and augmentation of myocardial blood flow. Since
coronary autoregulation is completely exhausted in these
patients, myocardial blood flow is directly dependent on
perfusion pressure. Because of that exhausted flow reserve, a
positive effect of augmented perfusion pressure is well
conceivable [18].
The prognosis in patients with PI treated medically is poor.
Rezkalla et al. described a 30-day mortality of 12 % in 64
patients who suffered from severely impaired myocardial
blush grade after PCI for AMI [11]. Mehta et al. confirmed
this poor prognosis with a 1-year mortality of 23 % in patients
with STEMI undergoing primary PCI with final TIMI ≤2 flow
[10]. Because of this poor prognosis, the value of attempts to
relieve PI is undisputable.
In our study, patients treated with IABP for PI had a
favourable 30-day survival of 93 % and a 1-year survival of
89 %. Since this study was performed retrospectively, there is
no control group. Outcome data can therefore only be
compared with the historical data, but are favourable and
mandate further randomised studies in such patients with
STEMI undergoing primary PCI complicated by PI.
Favourable long-term survival rates have been described
after IABP support in myocardial infarctions in non-
randomised studies [19]. A randomised trial (CRISP-AMI)
on adjunctive IABP therapy to limit infarct size in patients
with AMI in the absence of CS, failed to show benefit of IABP
treatment [20]. All-cause mortality at 6 months was less in the
IABP group (1.9 % versus 5.2 %; P=0.12), but was not
statistically significant due to the low rate of events
(underpowered study).
Table 2 Multivariate regression
analyses of 30-day survival in all
patients treated with IABP and 1-
year survival in patients who
survived until weaning of IABP
CABG indicates coronary artery
bypass grafting; CI confidence
intervals, CPR cardiopulmonary
resuscitation, IABP intra-aortic
balloon pump, OR odds ratio
30-day follow up 1-year follow up
OR 95 % CI p-value OR 95 % CI p-value
Age 1.03 1.00–1.06 0.06 1.04 1.0–1.08 0.03
Cardiogenic shock 4.7 1.8–12.4 0.002 1.8 0.7–4.6 0.19
CPR 1.8 0.8–3.7 0.13 2.2 1.0–5.3 0.06
Anti-arrhythmic drugs 1.1 0.5–2.2 0.80 1.2 0.5–2.7 0.65
Inotropic agents 2.9 0.9–9.7 0.08 2.6 0.7–8.9 0.14
CABG 0.3 0.1–0.6 0.002 0.3 0.1–0.8 0.01
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We believe IABP should not be used regularly in every
patient presenting with AMI, but there might be a subset of
patients – those with PI or no-reflow – who might benefit
from IABP support. In the presence of PI, this potentially
detrimental phenomenon might be bridged by using IABP
to reduce workload and oxygen demand of the myocardium
and increase myocardial perfusion. In this context, it has
been speculated in the literature whether timing of initiation
of IABP support is important, i.e. just before or after
opening of the occluded artery. A recent study with respect
to timing did not show any significant differences in odds of
mortality [21].
Limitations
This study is a retrospective analysis of all AMI patients but
with two fundamentally different characteristics (CS and PI).
There are no matched-control groups and the results of IABP
treatment in both groups had to be compared with historical
data. Furthermore, in the setting of no-reflow, additional
medical therapy is sometimes suggested, such as abciximab
or verapamil. In our study, none of these drugs were
systematically investigated. Verapamil was used in 4 patients,
while GP IIb/IIIa inhibitors were used only in 13 patients
because of angiographic signs of distal embolisation.
Nevertheless, this analysis of IABP use includes all
consecutive patients with AMI during 3 years within one large
heart centre, is not limited to the traditional CS patients but
also studied systematically patients with PI and is hypothesis-
generating for the future.
Conclusions
In this large retrospective study in 4076 consecutive patients
presenting with acute myocardial infarction during 3 years,
IABP was used in 6 % (n =239) of all cases because of two
different indications: cardiogenic shock (3.8 %) or persistent
ischaemia (2.2 %). Mortality in patients with cardiogenic
shock was high – but comparable with recent literature.
Outcome in patients with persistent ischaemia was favourable
when compared with historical data, and mandates further
prospective studies.
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